Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$3.34 - $6.98 $47,588 - $99,451
14,248 New
14,248 $96,000
Q1 2020

Apr 09, 2020

SELL
$4.28 - $12.11 $52,982 - $149,909
-12,379 Closed
0 $0
Q4 2019

Jan 16, 2020

BUY
$7.95 - $12.27 $98,413 - $151,890
12,379 New
12,379 $135,000

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $175M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Alpine Global Management, LLC Portfolio

Follow Alpine Global Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpine Global Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpine Global Management, LLC with notifications on news.